🇺🇸 FDA
Patent

US 10968261

Methods and compositions for genome engineering

granted A61KA61K48/00A61P

Quick answer

US patent 10968261 (Methods and compositions for genome engineering) held by Sangamo Therapeutics, Inc. expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K48/00, A61P, A61P3/00, A61P43/00